心衰死亡模式前的生物标志物、功能状态与生活质量轨迹:FINEARTS-HF 事后分析
本研究为 FINEARTS-HF 随机临床试验的事后分析,纳入 6001 例 HFmrEF 或 HFpEF 患者,中位随访 2.7 年,共发生 215 例猝死。结果显示猝死前 6 个月存在 NYHA 分级轻微恶化、KCCQ-TSS 约下降 8 分、NT-proBNP 从约 1800 pg/mL 升至 2000 pg/mL。其他死亡模式前也可见相似甚至更明显的恶化,提示这些改变对猝死缺乏特异性。
要点
- HFmrEF/HFpEF 患者猝死前 6 个月已出现症状、生活质量及 NT-proBNP 的轻微恶化
- 猝死前 KCCQ-TSS 约下降 8 分,NT-proBNP 从约 1800 升至 2000 pg/mL
- 其他死亡模式前出现相似或更明显的恶化,该轨迹对猝死缺乏特异性
核心结论
- 在当代 HFmrEF 或 HFpEF 队列中,猝死前存在症状轻微恶化、生活质量下降和利钠肽水平升高,提示许多此类事件可能并非完全突然发生。
- 其他死亡模式前也可见相似的恶化,提示这些临床轨迹对猝死的特异性有限。
研究设计与样本
- 本研究为 FINEARTS-HF 随机临床试验的事后分析,该试验为全球事件驱动临床试验。
- 纳入症状性心衰、LVEF≥40%、NYHA II–IV 级且 NT-proBNP 升高的患者,入组时间为 2020 年 9 月 14 日至 2023 年 1 月 10 日。
- 共纳入 6001 例患者,平均年龄 72.0 岁,男性 3269 例(54%),中位随访 2.7 年。
- 采用线性混合效应模型结合限制性立方样条,比较猝死前 NYHA 分级、KCCQ-TSS 和 NT-proBNP 的纵向轨迹与幸存者及其他死亡模式的差异。
主要发现
- 随访期间共发生 215 例猝死。
- 猝死前 6 个月内,NYHA 分级从约 2.3 轻度恶化至 2.4。
- 猝死前 6 个月内,KCCQ-TSS 出现约 8 分的下降。
- 猝死前 6 个月内,NT-proBNP 从约 1800 pg/mL 逐渐升至约 2000 pg/mL。
- 幸存者在随访结束前 18 个月内 NYHA 分级从约 2.3 改善至 2.1,KCCQ-TSS 从约 68 升至 77,NT-proBNP 从约 800 pg/mL 降至约 650 pg/mL。
临床怎么用
- HFmrEF/HFpEF 患者出现症状、生活质量及 NT-proBNP 的轻微恶化时,需警惕包括猝死在内的死亡风险。
- 单靠 NYHA 分级、KCCQ-TSS 或 NT-proBNP 的恶化难以区分即将发生的猝死与其他死亡模式。
局限性
- 本研究为事后分析,结果受原始试验设计和事后分析固有偏倚的影响。
- 猝死前观察到的临床恶化模式与其他死亡模式前的改变相似,对猝死的预测特异性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sudden death remains a leading cause of mortality in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF), but whether these events are preceded by clinical deterioration remains unclear. OBJECTIVE: To characterize clinical trajectories preceding sudden death in patients with HFmrEF or HFpEF and compare them with trajectories before other modes of death and survival. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the Finerenone Trial to Investigate the Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial evaluating trajectories of functional status, patient-reported health status, and natriuretic peptide levels preceding adjudicated modes of death. This was a global, event-driven clinical trial. Patients with symptomatic HF, left ventricular EF of 40% or greater, New York Heart Association class (NYHA) II to IV, and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) were enrolled between September 14, 2020, and January 10, 2023. Data analysis was conducted in December 2025. INTERVENTIONS: Finerenone vs placebo. MAIN OUTCOMES AND MEASURES: Longitudinal trajectories of NYHA class, Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS), and NT-proBNP levels preceding sudden death were compared with trajectories in survivors and those who died of HF-related, nonsudden cardiovascular, or noncardiovascular causes, using linear mixed-effects models with restricted cubic splines. RESULTS: Included in this analysis were 6001 patients (mean [SD] age, 72.0 [9.6] years; 3269 male [54%]). Over a median (IQR) follow-up of 2.7 (1.9-3.0) years, 215 sudden deaths occurred. In the 6 months before death, sudden death was preceded by a slight worsening in physician-assigned NYHA class (from approximately 2.3 to 2.4), worsening self-reported health status (an approximately 8-point decline in KCCQ-TSS), and a gradual rise in NT-proBNP levels (from approximately 1800 to 2000 pg/mL). In contrast, among patients who survived, NYHA class improved (from approximately 2.3 to 2.1), KCCQ-TSS increased (from approximately 68 to 77), and NT-proBNP levels declined (from approximately 800 to 650 pg/mL) over the 18 months before the end of follow-up. Comparable patterns of deterioration to those preceding sudden death, often more pronounced, were observed before other modes of death. CONCLUSIONS AND RELEVANCE: Results of this post hoc analysis of the FINEARTS-HF randomized clinical trial reveal that in this contemporary HFmrEF or HFpEF cohort, sudden death was preceded by modest worsening of symptoms, declining quality of life, and rising natriuretic peptide levels, suggesting many of these events may not have been entirely sudden. However, similar deterioration preceding other modes of death suggests limited specificity for sudden death. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.
引用
- Lu, Kosztin, Claggett, et al. Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41903171. doi:10.1001/jamacardio.2026.0682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。